以上内容基于公开资料整理，不构成投资建议。 股票近期走势 近7个交易日(2026年2月6日至13日)，宣泰医药股价区间下跌1.16%，最高价10.55元，最低价10.14元， 振幅3.95%。截至2月13日最新价10.25元，当日跌0.19%，换手率0.00%。资金流向方面，2月13日主力资 金净流入为0元，成交主要由散户主导。 经济观察网宣泰医药公告其产品熊去氧胆酸胶囊拟中选国家组织集采第1-8批协议期满品种接续采购， 若后续签订合同并实施，有望扩大销售规模和提高市场占有率。同日，公司持股5%以上股东Finer Pharma Inc.计划通过集中竞价或大宗交易减持不超过906.68万股(占总股本2%)，减持原因为股东自身资 金需求，减持期间为2026年3月11日至6月10日。 ...

Core Viewpoint - The company is focusing on high-end generic drugs while accelerating the development of improved new drugs, with a specific emphasis on the antifungal field through its self-developed project XT-0043, which has shown excellent safety and efficacy in Phase II clinical trials and is moving towards Phase III trials [2] Group 1 - The company is deeply engaged in the high-end generic drug market [2] - The first self-developed improved new drug project, XT-0043, is aimed at the antifungal area [2] - XT-0043 has demonstrated outstanding safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [2] Group 2 - The company is currently focusing on advancing the Phase III clinical trial based on the data obtained from Phase II [2]

Group 1 - The company, Xuantai Pharmaceutical (688247.SH), currently has no involvement in the development of AI innovative drugs [1]

Group 1 - The company, Shanghai Xuantai Pharmaceutical Technology Co., Ltd., has participated in the national organized procurement for the first to eighth batches of expiring agreements and has been proposed for selection in the continuation procurement for its product, ursodeoxycholic acid capsules [1] - The proposed selection will allow medical institutions to prioritize the use of the selected drug, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's sales scale, market share, and brand influence [1] Group 2 - The final selection data will be based on the results published by the continuation procurement office [1]

Group 1 - The core point of the article is that Xuantai Pharmaceutical announced its participation in the national organized procurement for drugs whose agreements have expired, specifically regarding the procurement of ursodeoxycholic acid capsules [2] - The company received notification from the procurement office on February 10, 2026, indicating that its product is proposed to be selected in the continuation of the procurement process [2]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

上海宣泰医药科技股份有限公司自愿披露 关于公司产品拟中选国家药品接续采购的公告 证券代码：688247 证券简称：宣泰医药 公告编号：2026-008 三、风险提示 公司拟中选产品的采购合同签订等后续事项以及带量采购后市场销售执行 情况尚具有不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义 务，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 2026 年 2 月 11 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）参与了国家组 织集采第 1-8 批协议期满品种接续采购的申报，根据国家组织集采药品协议期满 品种接续采购办公室（以下简称"接续采购办公室"）于 2026 年 2 月 10 日发布 的《国家组织集采药品协议期满品种接续采购拟中选结果表（LC-YPJX-2026-1）》 显示，公司产品熊去氧胆酸胶囊拟中选本次接续采购，现将相关情况公告如下： 注：上述信息均以接续采购办公室发布的最终中选数据为准。 二、本次拟中选对公司的影响 本次第 1-8 ...

Core Viewpoint - The company Xuantai Pharmaceutical (688247.SH) has announced its participation in the national centralized procurement for the continuation of products whose agreements have expired, with its product ursodeoxycholic acid capsules expected to be selected in this procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the national centralized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Market Impact - The procurement process prioritizes the use of selected drugs by medical institutions, ensuring the completion of the agreed purchase volume [1] - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products, increase market share, and enhance brand influence [1] - This development is expected to have a positive impact on the company's future operating performance [1]

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the national centralized procurement for the continuation of products from the first to eighth batches, with its product, ursodeoxycholic acid capsules, being proposed for selection in the continuation procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the continuation procurement of products whose agreements have expired, as announced by the continuation procurement office on February 10, 2026 [1] - The proposed selection of the company's product indicates a potential for increased sales and market share [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will likely enhance the sales scale and brand influence, positively affecting future operational performance [1]

Core Viewpoint - Xuantai Pharmaceutical (688247.SH) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with its product, ursodeoxycholic acid capsules, being proposed for selection in this procurement process [1] Group 1: Procurement Participation - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products [1] - The selection is expected to increase the company's market share and enhance brand influence, positively impacting future operating performance [1]